 | INAF - Indofarma Tbk. | INAF - Indofarma Tbk. | INAF - Indofarma Tbk. | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (2) | : | COMPOSITE, IDXHEALTH | ||
| Index (2) | : | COMPOSITE, IDXHEALTH | ||
| Board | : | 2 Index COMPOSITE, IDXHEALTH | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
| Special Notation | : | Ekuitas negatif. Perusahaan Tercatat memenuhi kriteria Efek Bersifat Ekuitas Dalam Pemantauan Khusus. | ||
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | ||||||
| D Good | ||||||
| E Fair | ||||||
| F Poor | |
|||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING FUNDAMENTAL | ||
|---|---|---|
| Rating EPS | 0 | |
| Rating ROA | 0 | |
| Rating EQUITY | 0 | |
| Rating ROE | 1 | |
| Rating DER | 0 | |
| Rating TOTAL | 0 | |
| MARKET CAPITALIZATION | ||
| Listed Share | 3.099.267.500 | |
| Price | Rp. 126 | |
| Capitalization | Rp. 390.507.705.000 | |
| OWNERSHIP | ||
| Listing Date : 36998 | ||
| Lokal 19,26 % | Asing 0,08 % | Lainnya 80,66 % |
| INAF - Indofarma Tbk. | INAF - Indofarma Tbk. | INAF - Indofarma Tbk. | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (2) | : | COMPOSITE, IDXHEALTH | ||
| Index (2) | : | COMPOSITE, IDXHEALTH | ||
| Board | : | 2 Index COMPOSITE, IDXHEALTH | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
| Special Notation | : | Ekuitas negatif. Perusahaan Tercatat memenuhi kriteria Efek Bersifat Ekuitas Dalam Pemantauan Khusus. | ||
Financial Statements
| Description | 3Q18 | 3Q19 | 3Q20 | 3Q21 | 3Q22 | 3Q23 | 3Q24 | CAGR 5Y(%) |
| Last Price | 5900 | 1505 | 2860 | 2330 | 985 | 490 | 126 | |
| Market Cap | 18.3 T | 4.7 T | 8.9 T | 7.2 T | 3.1 T | 1.5 T | 390.5 B | -91.69 |
| BALANCE SHEET | ||||||||
| Cash | 30.2 B | 16.0 B | 27.1 B | 350.5 B | 269.3 B | 209.8 B | 7.7 B | -51.88 |
| Total Asset | 1.5 T | 1.3 T | 1.5 T | 2.3 T | 1.8 T | 1.5 T | 758.4 B | -41.66 |
| S.T.Borrowing | 910.7 B | 748.8 B | 569.0 B | 1.3 T | 986.9 B | 1.2 T | 1.4 T | |
| L.T.Borrowing | 121.5 B | 115.2 B | 436.3 B | 632.4 B | 500.0 B | 439.9 B | 308.8 B | |
| Total Equity | 491.3 B | 461.8 B | 486.1 B | 433.2 B | 325.2 B | -105.4 B | -970.6 B | -310.18 |
| INCOME STATEMENT | ||||||||
| Revenue | 739.2 B | 583.5 B | 749.3 B | 1.5 T | 904.9 B | 445.7 B | 137.9 B | -76.37 |
| Gross Profit | 192.7 B | 165.9 B | 183.5 B | 496.8 B | 76.3 B | 10.2 B | -11.8 B | -107.11 |
| Operating Profit | -9.3 B | -12.9 B | 6.9 B | 48.5 B | -160.1 B | -173.4 B | -129.7 B | 905.43 |
| Net.Profit | -35.1 B | -34.8 B | -18.9 B | 2.8 B | -183.1 B | -191.7 B | -166.5 B | 378.45 |
| EBITDA | 11.0 B | 2.9 B | 24.6 B | 70.2 B | -136.1 B | -152.7 B | -115.4 B | -4079.31 |
| Interest Expense | 36.9 B | 30.2 B | 25.7 B | 29.6 B | 29.0 B | 39.1 B | 37.5 B | |
| RATIO | ||||||||
| EPS | -11.32 | -11.24 | -6.09 | 0.91 | -59.07 | -61.84 | -53.7 | 377.76 |
| PER | -521.20 x | -133.90 x | -469.62 x | 2,560.44 x | -16.68 x | -7.92 x | -2.35 x | |
| BVPS | 158.53 | 149 | 156.83 | 139.76 | 104.93 | -33.99 | -313.18 | |
| PBV | 37.22 x | 10.10 x | 18.24 x | 16.67 x | 9.39 x | -14.41 x | -0.40 x | |
| ROA | -0.023 | -0.0263 | -0.0127 | 0.0012 | -0.101 | -0.1286 | -0.2195 | 734.60 |
| ROE | -0.0714 | -0.0754 | -0.0388 | 0.0065 | -0.5631 | 1.8195 | 0.1715 | 327.45 |
| EV/EBITDA | 1755.24 | 1908.3 | 400.14 | 125.04 | -31.37 | -19.02 | -18.3 | |
| Debt/Equity | 2.1 | 1.87 | 2.07 | 4.4 | 4.57 | -15.15 | -1.78 | |
| Debt/TotalCap | 0.68 | 0.65 | 0.67 | 0.81 | 0.82 | 1.07 | 2.28 | |
| Debt/EBITDA | 93.93 | 299.12 | 40.87 | 27.14 | -10.92 | -10.45 | -14.98 | |
| EBITDA/IntExps | 0.3 | 0.1 | 0.96 | 2.38 | -4.7 | -3.91 | -3.08 | -3180.00 |
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | ||||||
| D Good | ||||||
| E Fair | ||||||
| F Poor | |
|||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| MARKET CAPITALIZATION | ||
| Listed Share | 3.099.267.500 | |
| Price | Rp. 126 | |
| Capitalization | Rp. 391 B. | |
| OWNERSHIP | ||
| Listing Date : 36998 | ||
| Lokal 19,26 % | Asing 0,08 % | Lainnya 80,66 % |
| RATING FUNDAMENTAL | ||
|---|---|---|
| Rating EPS | 0 | |
| Rating ROA | 0 | |
| Rating EQUITY | 0 | |
| Rating ROE | 1 | |
| Rating DER | 0 | |
| Rating TOTAL | 0 | |
EARNING PER SHARE
| INAF - Indofarma Tbk. | INAF - Indofarma Tbk. | INAF - Indofarma Tbk. | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (2) | : | COMPOSITE, IDXHEALTH | ||
| Index (2) | : | COMPOSITE, IDXHEALTH | ||
| Board | : | 2 Index COMPOSITE, IDXHEALTH | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
| Special Notation | : | Ekuitas negatif. Perusahaan Tercatat memenuhi kriteria Efek Bersifat Ekuitas Dalam Pemantauan Khusus. | ||
| TIME PERIOD : 07-03-2025 | |||
| Close | 126 | Prev Close | 126 |
| Change | - | Range | 0-0 |
| Bid | 0 | Offer | 0 |
| Bid Volume | 0 | Offer Volume | 0 |
| Frequency | 0 | Value Rp.: 0 | |
| EARNING PER SHARE (% PRICE) | |||||
|---|---|---|---|---|---|
| Benchmark to Others : | |||||
| A Exceptional | |||||
| B Excellent | |||||
| C Very Good | |||||
| D Good | |||||
| E Fair | |||||
| F Poor | |
||||
| Percent (%) of Price |
≤ 0 |
0-1.05 | 1.05-2.3 | 2.3-4.23 | > 4.23 |
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | ||||||
| D Good | ||||||
| E Fair | ||||||
| F Poor | |
|||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |